drugset
drugset / Trial / NCT05805605

Allo HSCT Using RIC and PTCy for Hematological Diseases

NCT05805605 ↗

Phase 2 Recruiting 56 enrolled Masonic Cancer Center, University of Minnesota
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.

Timeline

Start
2023-05-01
Primary completion
2027-10-22
Completion
2028-10-22

Drugs

EvaluationDrugModalityDoseRoute
Background Allopurinol Small molecule 150 mg/m2 —
Background Allopurinol Small molecule 300 mg —
Background Cyclophosphamide Other / unclassified — Intravenous
Background Fludarabine Small molecule 30 mg/m2 Intravenous
Background Mycophenolate Mofetil Small molecule 15 mg/kg Intravenous
Background Mycophenolate Mofetil Small molecule 3 g Intravenous
Background Sirolimus Small molecule 2.5 mg/m2 Oral

Indications

Burkitt lymphoma T-cell non-Hodgkin lymphoma acute biphenotypic leukemia acute undifferentiated leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma chronic myeloid leukemia follicular lymphoma marginal zone lymphoma myelodysplastic syndrome with excess blasts-1 myelofibrosis plasma cell leukemia prolymphocytic leukemia